MedTrace Logo

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

NCT05877924 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-03-26

No results posted yet for this study

Summary

This study aims to evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and determine the dose limiting toxicity (DLT), maximum tolerable dose (MTD) (if any), recommended phase II dose (RP2D), and dosing regimen of NBL-020.

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

NBL-020 for Injection

NBL-020 for Injection, Q3W, i.v.

Sponsors & Collaborators

  • NovaRock Biotherapeutics, Ltd

    lead INDUSTRY

Principal Investigators

  • Yilong Wu · Guangdong Provincial People's Hospital, Guangzhou City, Guangdong Province, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2025-08-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05877924 on ClinicalTrials.gov